{"id":1001072,"date":"2026-09-08T07:34:54","date_gmt":"2026-09-08T11:34:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verastem-oncology-to-unveil-new-clinical-data-highlighting-the-best-in-class-potential-of-vs-7375-an-oral-kras-g12d-on-off-inhibitor-across-pancreatic-lung-and-colorectal-cancers\/"},"modified":"2026-09-08T07:34:54","modified_gmt":"2026-09-08T11:34:54","slug":"verastem-oncology-to-unveil-new-clinical-data-highlighting-the-best-in-class-potential-of-vs-7375-an-oral-kras-g12d-on-off-inhibitor-across-pancreatic-lung-and-colorectal-cancers","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verastem-oncology-to-unveil-new-clinical-data-highlighting-the-best-in-class-potential-of-vs-7375-an-oral-kras-g12d-on-off-inhibitor-across-pancreatic-lung-and-colorectal-cancers\/","title":{"rendered":"Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON\/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers"},"content":{"rendered":"

<\/p>\n

Verastem Oncology to Unveil New Clinical Data Highlighting the Best-in-Class Potential of VS-7375, an Oral KRAS G12D (ON\/OFF) Inhibitor, Across Pancreatic, Lung, and Colorectal Cancers<\/b><\/p>\n

Investor event and webcast to be held Wednesday, October 14, 2026, at 8:00 am ET<\/i><\/p>\n

BOSTON–(BUSINESS WIRE<\/a>)–
\nVerastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS\/MAPK pathway-driven cancers, today announced it will host an investor event on Wednesday, October 14, at 8:00 am ET to present initial efficacy and updated safety and tolerability data for VS-7375 in pancreatic, lung, and colorectal cancers from the ongoing TARGET-D clinical development program. The upcoming presentation will build on the clinical update reported<\/a> in June 2026 and provide the first broader safety and efficacy assessment of VS-7375 across these tumor types. VS-7375 is a potential best-in-class, potent and selective investigational oral KRAS G12D (ON\/OFF) inhibitor.<\/p>\n

\nVerastem\u2019s management team will be joined by Manuel Hidalgo Medina, M.D., Ph.D., a leading medical oncologist who serves as director of the Gastrointestinal Cancer Center at New York University (NYU) Langone Health and as a professor of medicine at NYU Grossman School of Medicine. Dr. Hidalgo is an investigator in the ongoing Phase 1 and Phase 2 trials evaluating VS-7375. Dr. Hidalgo has over two decades of experience in translational and clinical research in anti-cancer drug development with an emphasis on pancreatic cancer.<\/p>\n

Webcast Information
\n
<\/b>On October 14, 2026, at 8:00 am ET, a live audio webcast, along with accompanying slides, will be available under “Events & Presentations” in the Investor section of the Company’s website, https:\/\/investor.verastem.com\/events<\/a>. A replay of the webcast will be archived and available following the event.<\/p>\n

About VS-7375, an Oral KRAS G12D (ON\/OFF) Inhibitor & TARGET-D Clinical Program
\n
<\/b>VS-7375 is an investigational, potent and selective, oral KRAS G12D dual ON\/OFF inhibitor \u2013 a potential best-in-class molecule designed to bind both the active (ON) and inactive (OFF) states of KRAS G12D selectively and more potentially and completely than compounds targeting only one state of the protein.<\/p>\n

\nVerastem is evaluating VS-7375 across the TARGET-D clinical development program in patients with advanced KRAS G12D-mutant solid tumors. The program includes the Phase 1\/2 TARGET-D 101 (NCT07020221) dose-escalation, dose-expansion and combination trial, as well as three registration-directed Phase 2 trials currently enrolling patients:<\/p>\n